PATENT CLAIM ANALYSIS

Application Number: 15774842
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "352000"]

Abstract:
The present invention discloses new medical uses of phosphodiesterase 4 (PDE 4) inhibitors for treating dyslipoproteinaemia and of diseases when respectively correlated or associated with dyslipoproteinaemia or lipoprotein imbalance, in particular abnormally high low density lipoprotein (LDL) in blood or serum, such as endothelial dysfunction, cardiovascular diseases, in particular arteriosclerosis, myocardial infarction, stroke, peripheral artery disease, and vascular stenosis or restenosis, independent and distinct from inflammatory diseases or conditions such as inflammatory-associated cardiovascular pathology and cardiac hypertrophy. Accordingly the present invention allows reducing cardiovascular risks in new clinical settings, especially in circumstances of abnormal high LDL levels and especially LDL-cholesterol and LDL-triglyceride levels.

Claim (Index 14):
The method according to  claim 5 , wherein the prophylaxis and/or therapy is not correlated or associated with inflammatory-associated cardiovascular pathology.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 93.0
- Lexical Diversity: 1.58667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14801384', '14054588', '13283536', '15753790', '15481664']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7173104111601168
- 35 USC 102 Novelty (BERT): 0.5194315197999653
- Combined Prediction Score: 0.6975225220241017
- Mean Citation Score: 198.929958
- Max Citation Score: 201.14471
- Similarity Product: 99.74051717651516

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test